Preview

Современная ревматология

Расширенный поиск

Акласта - новый стандарт эффективности антирезорбтивной терапии. Одна инфузия в год

https://doi.org/10.14412/1996-7012-2008-462

Полный текст:

Литература

1. <div><p>Davidson MR. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 2003;48:39-52.</p><p>Heaney R.P. Advances in therapy for osteoporosis. Clin Med Res 2003;1(2):93-99.</p><p>Nguyen T.V., Center J.R., Eisman J.A. Osteoporosis: underdiagnosed and undertreated. Med J Aust 2004;180(5):18-22.</p><p>Щварц Г.Я. Фармакотерапия остеопороза. М.: МИА, 2002.</p><p>Риггз Б.Л., Мелтон III Л.Д. Остеопороз. Этиология, диагностика, лечение. М.: Бином, 2000.</p><p>Amin S., Felson D.P. Osteoporosis in men. Rheumatic disease clinics of North America 2001; 27(1): 19-47.</p><p>Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.</p><p>Eastell R. Treatment of Postmenopausal Osteoporosis. N Engl Med J 1998; 338(11):736-46.</p><p>Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.</p><p>Mashiba T., Turner C.H., Hirano T. et al. Effects of suppressed bone turnover by bisphos-phonates on microdamage accumulation and bio-mechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28(5): 524-31.</p><p>Rodan G., Reszka A., Golub E. et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20(8):1291-300.</p><p>Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of post-menopausl osteoporosis. IJCP 2003; 57: 417-22.</p><p>Rogers M.J. et al. Cellular and Molecular Mechanisms of Action of Bisphosphonates Cancer 2000;88: 2961-8.</p><p>Mellstrom D.D., Sorensen O.H., Goemaere S. et al. Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis. Calcif Tissue Int 2004; 75(6):462-8.</p><p>Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21(12):1895-903.</p><p>Recker R.R., Weinstein R.S., Chesnut C.H. et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004; 15(3):231-7.</p><p>Black D., Cummings S., Karpf D. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.</p><p>Delmas P.D., Recker R.R., Chesnut C.H. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.</p><p>Rogers M.J. New insights into molecular mechanisms of action of bisphosphonates. Curr Pham Des 2003; 9:2643-58.</p><p>Pyon E.Y. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006; 28(4):475-90.</p><p>Harris S.T., Watts N.B., Genant H.K. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.</p><p>Reginster J., Minne H.W., Sorensen O.H. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.</p><p>Hodsman B., Hanley D.A., Josse R. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8):1241-9.</p><p>Hughes D.E., Wright K.R., Uy H.L. et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-87.</p><p>Recker R., Ensrud K., Diem S. et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res 2004(19):45.</p><p>Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in post-menopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241-49.</p><p>Bone H.G., Hosking D., Devogelaer J.P. et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in post-menopausal women. N Engl J Med 2004;350(12):1189-99.</p><p>Ensrud K.E., Barrett-Connor E.L., Schwartz A. et al. Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19(8):1259-69.</p><p>Boivin G.Y., Chavassieux P.M., Santora A.C. et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27(5): 687-94.</p><p>Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties. J Bone Miner Res 1999; 14: 1768-78.</p><p>Pecherstorfer M., Steinhauer E.U., Rizzoli R. et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003; 11(8):539-47.</p><p>Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in post-menopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-22.</p><p>Black D.M., Delmas P.D., Eastell R. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med 2007;356:1809-22.</p><p>Body J.J., Lortholary A., Romieu G. et al. A dose-finding study of zoledronate in hypercal-cemic cancer patients. J Bone Miner Res 1999;14:1557-61.</p><p>Omizo M., McClung M., Minkoff J. et al. A single annual infusion is preferred to oral weekly treatment in postmenopausal women with low bone mineral density previously treated with Alendronate. Abstr. Twenty-eighth annual meeting of ASBMR 2006;21(1):2313.</p><p>Saag K., Lindsay R., Kriegman A. et al. A single zolendronic acid infusion reduced bone resorption markers more rapidly then weekly oral alendronate in postmenopausal women wit low bone mineral density. Bone 2007; 40(5): 1238-43.</p><p>Lyles K.W., Colon-Emeric K.S., Magaziner J.S. еt al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007;357:1799-809.</p></div><br />


Для цитирования:


Мкртумян А.М., Недосугова Л.В., Бирюкова Е.В., Мкртумян А.М., Недосугова Л.В., Biryukova Y.V. Акласта - новый стандарт эффективности антирезорбтивной терапии. Одна инфузия в год. Современная ревматология. 2008;2(1):65-69. https://doi.org/10.14412/1996-7012-2008-462

For citation:


Mkrtumyan A.M., Nedosugova L.V., Biryukova E.V., Mkrtumyan A.M., Nedosugova L.V., Biryukova Y.V. Aclasta is a new standard of the efficiency of antiresorptive therapy: One-ayear infusion. Modern Rheumatology Journal. 2008;2(1):65-69. (In Russ.) https://doi.org/10.14412/1996-7012-2008-462

Просмотров: 692


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)